Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Wedbush restated their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) in a research note released on Tuesday,Benzinga reports. Wedbush currently has a $18.00 price target on the stock. ARTV has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target […]
More Stories
Age of Attraction Season 2? Renewal, Couples, Release Date, and Trailer
After a positive review of the debut of season 1 on March 11, 2026, people are craving more for the...
‘Bob’s Burgers’ Actor Identified as Driver Rescued From Fiery New Hampshire Crash
By Haika Mrema Actor and comedian Eugene Mirman has been identified as the driver rescued from a burning vehicle following...
Trump Says Pam Bondi Is out as His Attorney General
By Matthew Vadum President Donald Trump said on April 2 that Pam Bondi will no longer be the U.S. attorney...
US Military Says More Than 12,300 Iranian Targets Struck So Far
By Jack Phillips The U.S. military has provided an operational update on the month-long war with Iran, announcing that more...
What to Expect from the March Jobs Report
By Andrew Moran The March jobs report, scheduled for release on April 3, will mark the end of a quarter...
Russia Bans Producers From Exporting Gasoline
By Guy Birchall Russia extended a temporary ban on gasoline exports to producers, Moscow said on April 2, citing the...